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Abstract
Osteopontin (OPN) has been shown to promote colorectal cancer (CRC) progres-
sion; however, the mechanism of OPN-induced CRC progression is largely unknown.
In this study, we found that OPN overexpression led to enhanced anchorage-inde-
pendent growth, cell migration and invasion in KRAS gene mutant cells but to a les-
ser extent in KRAS wild-type cells. OPN overexpression also induced PI3K signalling,
expression of Snail and Matrix metallopeptidase 9 (MMP9), and suppressed the
expression of E-cadherin in KRAS mutant cells. In human CRC specimens, a high-
level expression of OPN significantly predicted poorer survival in CRC patients and
OPN expression was positively correlated with MMP9 expression, and negatively
correlated with E-cadherin expression. Furthermore, we have found that 15 genes
were co-upregulated in OPN highly expression CRC and a list of candidate drugs
that may have potential to reverse the secreted phosphoprotein 1 (SPP1) gene sig-
nature by connectivity mapping. In summary, OPN is a potential prognostic indicator
and therapeutic target for colon cancer.
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1 | INTRODUCTION
Colorectal cancer (CRC) is the third most common malignancy world-
wide, it has been reported that about 1.3 million cases of CRC are
diagnosed every year.1 The tumour development involves multi-steps
process over years and mostly occurs in the ageing population.2
Despite traditional surgery, chemotherapy and radiotherapy, the
prognosis of CRC remains poor. Some specific gene mutation leads
to tumour aggression in CRC. KRAS gene mutation is commonly
observed in the early stages of the adenoma-adenocarcinoma
sequence in human CRC development.3,4 KRAS mutations occur in
30%-40% of all cases of CRC. However, to date, specific therapeutic
agents against KRAS-mutated CRC have not been developed.4 The
potential correlation between KRAS and other oncogene remains to
be further investigated. Osteopontin (OPN) is a 34 kD integrin-bind-
ing glycophosphoprotein, which plays an important role in cancer
progression and is considered as a potential biomarker for cancer
prognosis.5,6 It is encoded by SPP1 gene that has five isoform vari-
ants, which include OPN-a, OPN-b, OPN-c, isoform 4 and isoform
5.5 OPN has been previously found to be highly expressed in colon
cancer cells or tissues than that in normal intestinal epithelial cell line
or corresponding normal colon tissues.7 Up-regulation of OPN
increased cell motility in vitro, tumorigenesis and angiogenesis
in vivo,8 and predicted patient survival in colon cancer.9 Therefore,
OPN has been recognized as a potential target for human colon can-
cer.10 However, the upstream and downstream effectors in OPN
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overexpression (OPN OE) of colon cancer are still largely unknown.
In this study, we investigated the role of OPN overexpression
related to phenotypic changes using KRAS mutant and KRAS wild-
type colon cancer cells. We further identified potential downstream
targets involved in OPN overexpression-mediated colon cancer pro-
gression. In addition, we also carried out the connectivity mapping
analysis to identify potential therapeutic drug candidates for OPN-
overexpressing colon cancer.
2 | MATERIALS AND METHODS
2.1 | Cell culture
Isogenic pair of Duke Stage C colorectal cancer cells DLD1 with
DKS8 were selected. DLD1 expresses heterozygous Kras G13D
mutation and the isogenic cell, DKS8 had the Kras G13D mutation
knocked out at its endogenous locus.11 The parental (DLD1), normal
epithelial (FHC) and Phoenix-AMPHO cell lines purchased from
ATCC, while the isogenic cell lines were gifts from Prof. Senji Shira-
sawa’s Laboratory. These cell lines were grown in cell culture media
DMEM/F-12 (Gibco: Cat. no. 1320033) with 10% foetal bovine
serum and 1% penicillin/streptomycin. FHC medium prepared with
additional 10 mmol/L HEPES, 10 ng/mL cholera toxin, 5 ng/mL
transferrin, 5 ng/mL insulin and 100 ng/mL hydrocortisone.
2.2 | Retroviral Infection and stable cell line
transfection
The p3XFLAG-CMV-7.1 (Sigma, E7533) was ligated to the N-term-
inal of OPN-c gene of pcDNA3-OPN-V5, which was a gift from Ste-
ven Johnson (Addgene plasmid # 11617).12 Then it was inserted into
pBABE-puro which was a gift from Hartmut Land, Jay Morgenstern
and Bob Weinberg (Addgene plasmid # 1764).13 Phoenix-AMPHO
cells were used to produce the retrovirus to transduce the DLD1
and DKS8. The expression level of OPN in these stable cell lines
was determined with Western blotting.
2.3 | Total protein quantification and Western
blotting
The cell line samples were homogenized with ice-cold RIPA lysis buf-
fer that was added with protease inhibitor (Complete EDTA-free,
#10634200, Roche) and phosphatase inhibitor (PhosSTOP,
#04906837001, Roche) and centrifuged at 20 0009 g for 30 min-
utes at 4°C. Supernatants were collected and kept in 80°C. BCA
method was used to quantify the protein concentration required for
Western blot sample loading (Pierce BCA Protein Assay Kit,
#23225). All samples were dissolved in LDS sample buffer and
reducing agent (Life Technologies) and heated for 5 minutes at
95°C. An equal concentration of proteins was electrophorized and
separated with TGX Stain-FreeTM FastCastTM Acrylamide Kit, 12% and
transferred to a 0.2 lm nitrocellulose membrane (#IB401002) mem-
branes. Blocking was carried out with 5% non-fat milk, 0.1% Tween
20 in PBS for non-specific binding for an hour at room temperature.
The membranes were incubated overnight at 4°C with respective
antibodies: anti-FLAG (1:2000, F1804, Sigma), anti-MMP9, 2c3,
(1:500, sc-21733, Santa Cruz Biotechnology), anti-b-catenin (1:500;
Abcam, Cambridge, MA), anti-Akt antibody (Cat. 9272, Cell Sig-
nalling), anti-p-Akt antibody (1:1000, Cat. 9271, Cell Signalling), anti-
Phospho-GSK-3b (Ser9) (1:1000, Cat.5558, Cell Signalling), anti-GSK-
3b (1:1000, Cat.9315, Cell Signalling), anti-Snail antibody (1:1000,
ab180714),anti-E-Cadherin (24E10) (1:1000, Cat. 3195, Cell Sig-
nalling), anti-N-Cadherin (D4R1H) (1:1000, Cat. 13116, Cell Sig-
nalling) and normalized with anti-b-actin, C4 (1:5000, sc-47778,
Santa Cruz Biotechnology). The membranes were washed, incubated
for an hour at room temperature with respective secondary antibod-
ies and detected with chemiluminescent HRP substrate reagent (1:1)
(Immobilon Western, WBKLS0500, Millipore) using ChemiDoc MP
Imaging System (Bio-Rad).
2.4 | Soft agar colony formation assay
Soft agar assays were carried out in a 6-well plate, each sample in trip-
licate and colonies were counted on day 15 after plating. The base
layer consisted of 2 mL with a final concentration of culture medium
and 0.6% low melting temperature agarose (Lonza). Next, the respec-
tive cells were seeded with culture medium containing 0.6% agar to
result in a final concentration of was 0.3% agarose with 5 x 104 cells.
A further 500 lL culture medium only was added above the congealed
middle agar layer on the next day. The colonies were captured at five
random fields at 409 magnification with inverted phase microscope
(Leica), measured using the Leica software. The scale was set at ImageJ
to select colony size more than 0.45 mm.
2.5 | Proliferation assay
Cell proliferation was measured using a bright field image label-free
high-content time-lapse assay system (IncuCyte Zoom system; Essen
BioScience) according to the manufacturer’s instructions. In brief, for
the proliferation assay, equal numbers of cells (1 9 103 cells/well)
were seeded on to 96-well plate in the 200 lL culture medium with
supplements or agents, and per cent cell confluence was then continu-
ously measured using the IncuCyte system over a 5-day period.
2.6 | Wound healing assay
Each cell line group consists of OPN OE and control (pBABE puro).
The initial seeding density was 2 9 104 and 4 9 104 cells/100 lL
growth medium in a 96-well plate (Image Lock plates, Essen Bio-
science), respectively, for DLD1 and DKS8 cells, and left to reach
fully confluence before wounding with a wound maker (Essen Bio-
science). The plates were replaced with the new medium (200 lL)
before further incubated and visualized for 60 hours at 37°C in the
IncuCyte. Wound width was measured every two hours and images
were captured at set time 4009 magnification. This experiment was
repeated three times.
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2.7 | Transwell migration/invasion assay
Migration and invasion transwell assays were performed using 24-well
transwell inserts (Cell Biolabs, Inc.). The cells were starved for 16-
18 hours prior seeding. The migration plates contained inserts with
polycarbonate membrane with 8 mm size pores, while the invasion
plated contained ECM-coated cell culture inserts. Cells (1 9 105) sus-
pended in serum-free media were added into each insert and 500 lL
media consist of 30% FBS was added to the bottom chamber of each
well. Cells were left for 48 hours and non-migratory/non-invasive cells
were removed as much with cotton swabs. The inserts were stained
with 400 lL of Cell Stain Solution and incubated at room temperature
for 10 minutes. The migratory/invasive cells were photographed with
Carl Zeiss Axio Observer with five random fields (10 objectives) per
insert. After that, transfer each insert to an empty well, adding 200 lL
of Extraction Solution per well, then incubating 10 minutes on an orbi-
tal shaker. Transfer 100 lL from each sample to a 96-well microtitre
plate and measure the OD 560 nm in a plate reader. This experiment
was repeated three times.
2.8 | Extraction of clinical and microarray gene
expression data from colon cancer patient datasets
Two colon cancer patient datasets available in the Gene Expression
Omnibus database were included in this study as previously
described.14 Microarray gene expression data were retrieved from the
data matrices and R scripting was used to extract the expression val-
ues of genes of interest and the clinical data from the data matrices.
The median expression value was used as a cut-off point for high and
low levels expression for survival analysis. The details of the data
extraction method and R script referred to the previous publication.15
2.9 | Connectivity mapping
Gene expression connectivity mapping was performed using the
algorithms in the framework of Statistically Significant Connection’s
Map (sscMap)16,17 to identify candidate small molecule compounds
that may inhibit the expression of genes that are co-regulated in
OPN-overexpressing colon cancer. OPN and 15 co-regulated genes
(see Section 3.5 below) formed a gene signature for connectivity
mapping. The compiled gene signature was then fed to the Java
application sscMap as a query signature, and its association with a
large collection of reference gene expression profiles were com-
pared. In this study, we used the reference gene expression profiles
recently released with the QUADrATiC system,18 covering data for
over 1000 FDA approved drugs from the LINCS database (https://c
lue.io/). The gene signature perturbation procedure,19 which
increases the specificity of the output results, was applied. All the
small molecular compounds, that were negatively associated with
the OPN Gene Expression Signature, were sorted and ranked by
their P-value, perturbation stability and standardized connection
score. As we are only interested in inhibitory compounds, one-tailed
P-values were used. To effectively control false positive discoveries,
a stringent P-value threshold was set as 1/N = 1/1432 = .0007,
where N = 1432 is the number of FDA drugs screened here. Any
drugs with a P-value smaller than the set threshold are considered
statistically significant (those above the blue line in Figure 1). These
criteria control the expected number of falsely significant drugs at 1,
as previously described and justified for multiple testing issues.20,21
Given the number of significant drugs as 95 in this study, the overall
false discovery rate of our results is approximately 1% (1/95). The
top 20 small molecules were searched together with colon cancer
using the PubMed search engine to identify research articles that
have described their effects on the treatment of colon cancer.
3 | RESULTS
3.1 | Overexpression of OPN in colon cancer cells
with mutant KRAS
To evaluate the role of OPN overexpression in colon cancer, FLAG-
tag OPN was overexpressed in DLD1 colon cancer cell lines (Fig-
ure 2A). As shown in Figure 2, overexpression of OPN did not sig-
nificantly increase cell proliferation (Figure 2B). OPN overexpression
significantly increased cell migration as demonstrated by wound
F IGURE 1 Connectivity mapping of OPN gene signatures.
Connectivity mapping shows the results of gene expression using
the OPN gene signature as query to sscMap and the QUADrATiC
collection of reference profiles for FDA approved drugs. The blue
line in the figure represents the P-value threshold (.0007) as
described above, where it intersects the vertical axis at log10
(0.0007) = 3.16. The number of significant drugs (above the blue
line, red or green spots) is 95, and the number of green spots (drugs
with perturbation stability = 1) is 53, which all are listed in Table 1.
The full results of connectivity mapping to all 1432 drugs can be
found in Table S1
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closure assay (Figure 2C) and transwell migration assay (Figure 2D),
and cell invasion as demonstrated by transwell invasion assay (Fig-
ure 2E) in DLD1 colon cancer cells. Overexpression of OPN in DLD1
cells also significantly increased its ability to form colony in soft agar
assay (Figure 2F).
3.2 | Overexpression of OPN in colon cancer cells
with wild-type KRAS
As DLD1 contains mutant KRAS while it has an isogenic KRAS wild-
type DKS8 generated previously,22 FLAG-tag OPN was overex-
pressed in DKS8 cells (Figure 3A) and its phenotype was investi-
gated. As shown in Figure 3, overexpression of OPN again did not
significantly increase cell proliferation in DKS8 cells (Figure 3B).
OPN overexpression did not significantly increase cell migration in
wound closure assay (Figure 3C), but slightly and significantly
increased cell migration in transwell migration assay (Figure 3D) and
cell invasion in transwell invasion assay (Figure 3E). Overexpression
of OPN did not significantly increase anchorage-independent growth
of DKS8 cells (Figure 3F).
3.3 | OPN overexpression enhanced oncogenic
signalling dependent on KRAS mutation status
As shown in Figure 4, OPN overexpression in DLD1 cells resulted
in increased Akt phosphorylation in an activation site and GSK-3b
phosphorylation in an inhibitory site, suggesting OPN may activate
PI3K signalling pathway. Besides, we observed an increased in
b-catenin, MMP9 and Snail, and decreased in E-cadherin, suggest-
ing potential epithelial-mesenchymal transition by OPN overexpres-
sion in DLD1 cells. These changes induced by OPN
overexpression were not observed in DKS8 cells, suggesting that
OPN may induce the oncogenic signal in KRAS mutant dependent
manner.
F IGURE 2 Phenotype changes of OPN overexpression in DLD1. A, Western blot analysis of FLAG-tag OPN level in OPN OE and control
group, b-actin was used as a control. B, Cell proliferation was recorded for 7 d using the IncuCyte instrument, mean  SD (error bars, n = 9).
C, Cell migration was measured by wound closure over 72 h using the IncuCyte, mean  SD (error bars, n = 9). D, The migration rates
determined and analysed after 48 h with Boyden Chamber assay. Images are representative sections of one well at 20x. E, The invasion rates
determined and analysed after 48 h with Boyden Chamber assay. Images are representative sections of one well at 20x. F, Cells were seeded
in a 0.6% agar/growth medium layer and its colony formation was measured after 15 d of cultivation. The graphs indicate the mean  SD, of
triplicate wells counted using ImageJ software and the images are representative sections of one well at 40x. “*,” “**” and “***” indicate
P < .05, P < .01 and P < .001, respectively, and statistically analysed with T-test
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3.4 | The prognostic significance of OPN
overexpression in colon cancer
To investigate whether OPN expression is a prognostic marker in
colon cancer, two colon cancer datasets in GEO database previously
described13,14 with available data on OPN expression, disease-speci-
fic survival were included in this study, namely GSE1433323 and
GSE17538.24 In GSE14333 colon cancer patient cohort with avail-
able clinical information (n = 226), we found that patients whose
tumour expressed a high-level expression of OPN had a mean sur-
vival time of 74.4 months (95% CI = 64.6-84.2 months), which was
significantly shorter compared to those patients whose tumour
expressed a low level of OPN, who had a mean survival time of
120.8 months (95% CI = 110.3-131.3 months, P = .004; Figure 5A).
In GSE17538 colon cancer patient cohort with available clinical
information (n = 232), we found that patients whose tumour
expressed a high-level expression of OPN had a mean survival time
of 78.6 months (95% CI = 66.2-91.0 months), which was signifi-
cantly shorter compared to those patients whose tumour expressed
a low level of OPN, who had a mean survival time of 113.5 months
(95% CI = 102.6-124.5 months, P < .001; Figure 5B). Our results
confirm that OPN is a potential prognostic marker in colon cancer
patients.
3.5 | Identification of genes that were associated
with OPN overexpression
From these two colon cancer patient datasets, we have divided the
patients into two groups in each dataset based on the expression
level of OPN in their tumours. We have identified the top 15 genes
that were differentially expressed in these two groups consistently
in the two datasets. These 15 genes were CLEC5A, TREM2, OLR1,
C5AR1, GPNMB, POSTN, CTSL1, TYROBP, CD163, PRRX1, FCER1G,
BCAT1, TREM1, FCGR2C and NCF2. Indeed, from these two datasets,
F IGURE 3 Phenotype changes of OPN overexpression in DKS8. A, Western blot analysis of FLAG-tag OPN level in OPN OE and control
group, b-actin was used as a control. B, Cell proliferation was recorded for 7 d using the IncuCyte instrument, mean  SD (error bars, n = 9).
C, Cell migration was measured by wound closure over 72 h using the IncuCyte, mean  SD (error bars, n = 9). D, The migration rates
determined and analysed after 48 h with Boyden Chamber assay. Images are representative sections of one well at 20x. E, The invasion rates
determined and analysed after 48 h with Boyden Chamber assay. Images are representative sections of one well at 20x. F, Cells were seeded
in a 0.6% agar/growth medium layer and its colony formation was measured after 15 d of cultivation. The graphs indicate the mean  SD, of
triplicate wells counted using ImageJ software and the images are representative sections of one well at 40x. “*,” “**” and “***” indicate
P < .05, P < .01 and P < .001, respectively, and statistically analysed with T-test
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we also found that OPN expression was negative correlated with E-
cadherin expression (GSE14333: r = .355, P < .001 and GSE17538:
r = .165, P = .012) and was positive correlated with MMP9 expres-
sion (GSE14333: r = .442, P < .001 and GSE17538: r = .484,
P < .001), consistent with our findings in vitro in DLD1 cell line.
3.6 | Identification of small molecules that can
reverse OPN gene signature
Using connectivity mapping, OPN and the top 15 OPN co-regulated
genes, we have identified 53 small molecules that could potentially
reverse colon cancer OPN gene (SPP1) signature passing the pertur-
bation stability test (Table 1) among 1432 candidate drugs. The full
results of all 1432 drugs are attached in “Table S1.” The top five
small molecules are bendroflumethiazide, calcitriol, benzoic acid,
memantine and sibutramine.
4 | DISCUSSION
In this study, we established OPN stable overexpressing cells using
KRAS mutant/wild-type isogenic pair of colon cancer cell line to
investigate the potential role and mechanism of OPN overexpression
in colon cancer progression. Our results suggest that overexpression
of OPN promote colon cancer cell migration and invasion, and
anchorage-independent growth significantly in the presence of
mutant KRAS and to a lesser extent in the wild-type KRAS
F IGURE 4 Overexpression of OPN effect on KRAS signalling pathway. A, Western blot analysis of OPN OE. B, Predicted signalling
pathways involved in OPN overexpression in KRAS mutant CRC
F IGURE 5 Kaplan-Meier survival analysis for OPN expression in
colon cancer patient cohorts. Kaplan-Meier survival analysis for OPN
expression in A, GSE14333 and B, GSE17538 colon cancer datasets
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TABLE 1 Candidate drugs that may have the potential to reverse the SPP1 gene signature
Compound Replicate P value zscore Significance_mark Perturb_stability
BRD-A80017228__bendroflumethiazide 140 1.51E-11 6.645712778 1 1
BRD-A66229260__calcitriol 27 3.15E-10 6.182628333 1 1
BRD-K53397409__benzoic-acid 27 3.54E-10 6.16412438 1 1
BRD-A79803969__memantine 53 5.18E-09 5.72465667 1 1
BRD-A23359898__sibutramine 77 6.60E-09 5.683522877 1 1
BRD-K02992638__lamivudine 95 6.74E-09 5.679906593 1 1
BRD-A62434282__goserelin 48 1.37E-08 5.556859227 1 1
BRD-A35258977__mannitol 25 3.85E-08 5.374021465 1 1
BRD-A65013509__oxybutynin 45 7.32E-08 5.257119145 1 1
BRD-K91315211__betahistine 75 7.71E-08 5.247492361 1 1
BRD-A29426959__carbinoxamine 126 1.12E-07 5.178125706 1 1
BRD-A49172652__lansoprazole 45 1.15E-07 5.173084601 1 1
BRD-K94436377__diosmin 12 1.38E-07 5.139469425 1 1
BRD-A88774919__doxycycline 45 3.06E-07 4.987137365 1 1
BRD-K34157611__cimetidine 90 3.40E-07 4.967242256 1 1
BRD-A67097164__ifosfamide 38 6.44E-07 4.841514805 1 1
BRD-A10386413__ascorbic-acid 26 8.01E-07 4.798100724 1 1
BRD-K44497846__enalapril 45 1.00E-06 4.753272058 1 1
BRD-K45330754__diethylstilbestrol 542 2.49E-06 4.56598884 1 1
BRD-K55930204__phenytoin 45 2.60E-06 4.556400029 1 1
BRD-K71696703__triflusal 12 3.23E-06 4.510431872 1 1
BRD-A88208128__tetracycline 27 3.50E-06 4.493420086 1 1
BRD-K70976396__cefoxitin 56 3.73E-06 4.480358699 1 1
BRD-A16754160__ampicillin 70 5.08E-06 4.413784472 1 1
BRD-A07106394__tryptophan 27 5.72E-06 4.387838983 1 1
BRD-K15502390__nevirapine 81 6.34E-06 4.365424658 1 1
BRD-A34006693__suprofen 11 6.35E-06 4.365105537 1 1
BRD-A55815733__phylloquinone 45 7.02E-06 4.3432216 1 1
BRD-K21520694__sulfacetamide 99 7.25E-06 4.336298442 1 1
BRD-K41524689__paracetamol 11 7.71E-06 4.322594942 1 1
BRD-A24514565__warfarin 108 8.15E-06 4.310251978 1 1
BRD-A90515964__guaifenesin 65 8.47E-06 4.301828669 1 1
BRD-K89348303__ramipril 82 8.75E-06 4.294711525 1 1
BRD-K84091759__candesartan 11 9.11E-06 4.285769298 1 1
BRD-A43286952__ethinyl-estradiol 27 9.22E-06 4.283002437 1 1
BRD-A02759312__betaxolol 110 1.25E-05 4.214835372 1 1
BRD-K94353609__fluocinolone 88 1.35E-05 4.197053722 1 1
BRD-K65146499__nabumetone 64 1.41E-05 4.188246176 1 1
BRD-K34441861__moexipril 71 1.88E-05 4.121806342 1 1
BRD-K81839095__estrone 372 2.34E-05 4.070928448 1 1
BRD-K44876623__zolpidem 81 2.38E-05 4.067188474 1 1
BRD-M58473998__alimemazine 11 3.17E-05 3.999544267 1 1
BRD-K24844714__fluorouracil 142 3.62E-05 3.968351449 1 1
BRD-K54416256__methimazole 56 4.12E-05 3.937566409 1 1
BRD-K57930253__nitrazepam 37 4.22E-05 3.931721025 1 1
BRD-A74500471__ethambutol 46 4.75E-05 3.90293934 1 1
(Continues)
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counterpart. Indeed, OPN overexpression only activates oncogenic
signals, including Akt signalling, Snail, b-catenin and MMP9 in KRAS
mutant DLD1 cells, but not in KRAS wild-type DKS8 cells, suggesting
OPN-induced oncogenic signalling is dependent on activation of
KRAS.
We have identified the top 15 genes that were co-upregulated
with OPN in human colon cancer specimens. Based on online liter-
ature search, we found that OLR1, GPNMB, PRRX1 and BCAT1 pro-
mote cancer migration and invasion in various types of cancer.
Specifically, OLR1 has been recognized as a cell migration stimulator
in breast cancer cells, and potentially up-regulated by oncogene
TBC1D3 through activation of TNFa/NF-KB pathway.
25 Non-meta-
static glycoprotein melanoma protein B (GPNMB), also known as
osteoactivin (OA) is expressed in verified tumours and represents
an emerging target for drug development. For example, GPNMB/
OA increases the invasiveness of human metastatic prostate cancer
cell lines DU145 and PC3 through MMP2 and MMP9 activities,
and also enhances tumorigenesis of human lung cancer and breast
cancer26-28 PRRX1 promotes epithelial-mesenchymal transition
(EMT) through the Wnt/b-catenin pathway in gastric cancer and
also has been identified as a new EMT inducer in breast and col-
orectal cancer.29,30 Similarly, overexpression of BCAT1, a c-Myc tar-
get gene might associate with ovarian cancer progression and
induce cell proliferation, migration and invasion in nasopharyngeal
carcinoma.31,32 Some in vitro trials indicated that suppression of
BCAT1 could significantly decrease tumour proliferation in glioma
cell lines.33 It has been well known that OPN overexpression has
enhanced tumour behaviour, but the potential co-regulation genes
involved in this complex process have not been well identified. In
our previous work, we have shown that the expression of OPN
and MMP9 were positively correlated in human bladder cancer
specimens and bladder cancer cell lines.12 In the present study, we
found that overexpression of OPN up-regulated MMP9 while OPN
and MMP9 expression levels were positively correlated in two
independent colon cancer datasets. Our results demonstrated that
MMP9 may be a universal downstream target of OPN in both
colon and bladder cancer progression.
In the present study, we found a list of candidate drugs that may
have potential to reverse the OPN gene (SPP1) signature. On the top
of the list, calcitriol is one of the significant candidates that might
affect the OPN gene signature. Calcitriol (1,25-Dihydroxyvitamin D)
the most active metabolite of vitamin D, has significant anti-neoplas-
tic activity in preclinical models. There are some well-studied mecha-
nisms such as growth inhibition and accumulation in G0-G1,
associated with transcriptional activation of CDK inhibitors p27Kip1
and/or p21Waf1 as well as some other mitogenic signals, induction of
apoptosis, and inhibition of invasiveness and angiogenesis have also
been reported.34 Some reports indicated that calcitriol would enhance
radiation sensitivity in colorectal cancer regulated by the epithelial-
mesenchymal transition, for example, in vitro experiment trial of
DLD1 and HCT116, 24 hours calcitriol pre-treatment enhanced the
radiation sensitivity by 2.3- and 2.6-fold.35 Pre-clinical and epidemio-
logical studies have promoted the anti-tumour effect of calcitriol, par-
ticularly against colorectal cancer which involved in anti-proliferation,
pro-differentiation, pro-apoptosis, anti-angiogenesis, immune modula-
tion and miR regulation.36 A number of genes are recognized to con-
tain functional vitamin D response elements, which also include
OPN.34,37 Survival from colorectal cancer has been reported to be
positively associated with vitamin D status and OPN expression level,
respectively.5,38 The potential effect of calcitriol on OPN gene signa-
ture in colorectal cancer development warrant further investigation.
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TABLE 1 (Continued)
Compound Replicate P value zscore Significance_mark Perturb_stability
BRD-K15262564__mupirocin 45 4.90E-05 3.895436606 1 1
BRD-A15131297__benazepril 81 6.84E-05 3.81377276 1 1
BRD-M07438658__lapatinib 67 7.27E-05 3.798806938 1 1
BRD-K82225283__isosorbide 11 7.75E-05 3.782771087 1 1
BRD-A72441487__stiripentol 49 9.22E-05 3.739479613 1 1
BRD-K18895904__olanzapine 48 1.31E-04 3.650144317 1 1
BRD-A20348246__chlormezanone 10 1.33E-04 3.646768303 1 1
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